Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP "trapping" and what this means for both clinical monotherapy and combination with chemotherapeutic agents.
Copyright © 2016, American Association for the Advancement of Science.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Clinical Trials, Phase I as Topic
-
DNA Damage
-
DNA Repair
-
Enzyme Inhibitors / pharmacology
-
Female
-
Genes, BRCA1
-
Humans
-
Male
-
Maximum Tolerated Dose
-
Mutation
-
Neoplasms / drug therapy*
-
Neoplasms / pathology
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / pathology
-
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology*
-
Poly(ADP-ribose) Polymerases / chemistry*
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / pathology
-
Translational Research, Biomedical
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Poly(ADP-ribose) Polymerases